Current status of treatment for 2019 novel coronavirus pneumonia
10.3760/cma.j.issn.0254-5101.2020.0002
- VernacularTitle: 2019新型冠状病毒肺炎治疗研究现状
- Author:
Naiwei ZHU
1
;
Ping ZHAO
1
;
Zhongtian QI
1
Author Information
1. Department of Biomedical Defense, PLA Key Laboratory of Biodetection and Biodefense, Shanghai Key Laboratory of Medical Biodefense, Naval Medical University, Shanghai 200433, China
- Publication Type:Journal Article
- Keywords:
2019 novel coronavirus;
Treatment;
Drugs
- From:
Chinese Journal of Microbiology and Immunology
2020;40(1):E002-E002
- CountryChina
- Language:Chinese
-
Abstract:
2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease.
